Valuation: InspireMD, Inc.

Market Cap 32.86M 28.8M 26.62M 24.49M 46.2M 3.17B 46.94M 318M 125M 1.55B 123M 121M 5.34B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 32.86M 28.8M 26.62M 24.49M 46.2M 3.17B 46.94M 318M 125M 1.55B 123M 121M 5.34B EV / Sales 2026 *
3.17x
EV / Sales 2027 * 1.5x
Free-Float
80.17%
Yield 2026 *
-
Yield 2027 * -
1 day+0.91%
1 week-1.56%
Current month+1.10%
1 month-1.16%
3 months-47.57%
6 months-56.04%
Current year-60.24%
1 week 0.7
Extreme 0.7
0.72
1 month 0.63
Extreme 0.63
0.76
Current year 0.63
Extreme 0.63
1.98
1 year 0.63
Extreme 0.63
2.93
3 years 0.63
Extreme 0.63
3.85
5 years 0.63
Extreme 0.63
6.82
10 years 0.63
Extreme 0.63
161,504.13
Manager TitleAgeSince
Chief Executive Officer 62 2019-12-31
Director of Finance/CFO 58 2025-06-24
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 2017-06-01
Director/Board Member 68 2013-02-06
Director/Board Member 62 2019-12-31
Date Insider Type Main position Quantity % Market Cap.
5/27/26 Buy

Chairman

20,000 0.0427%
5/27/26
Osiris Investment Partners LLC
OtherCompany 0 0%
5/19/26 Sell

Executive/Senior Manager

-22,778 0.0486%
Change 5-day change 1-year change 3-year change Capi.($)
+1.14%-1.56%-71.88%-76.94% 32.86M
-0.18%-3.30%-17.25%+8.27% 123B
-1.13%-1.43%+0.84%-5.09% 13.03B
-0.76%+3.03%+62.67%+106.75% 9.21B
+1.67%+14.29%-42.45%-67.47% 4.47B
+0.98%+0.85%+6.39%+47.04% 2.7B
+0.80%-6.61%-22.01%-30.66% 1.62B
+3.55%+3.10%-9.81%-18.90% 1.6B
-0.89%+3.50%+3.31%-58.52% 1.56B
Average +1.01%+1.79%-10.02%-10.61% 17.43B
Weighted average by Cap. +0.50%-1.84%-11.14%+10.09%

Financials

2026 *2027 *
Net sales 10.38M 9.09M 8.41M 7.73M 14.59M 1B 14.82M 101M 39.4M 490M 38.96M 38.11M 1.69B 21.92M 19.21M 17.76M 16.33M 30.81M 2.11B 31.31M 212M 83.23M 1.03B 82.29M 80.5M 3.56B
Net income - -
Net Debt - -
Logo InspireMD, Inc.
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
127
Date Price Change Volume
26-07-20 US$0.7096 +1.14% 9,464
26-07-17 US$0.7016 -1.20% 10,360
26-07-16 US$0.7101 -1.38% 63,667
26-07-15 US$0.7200 +0.35% 26,122
26-07-14 US$0.7175 -0.21% 15,170
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.7016USD
Average target price
3.667USD
Spread / Average Target
+422.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NSPR Stock